Literature DB >> 6239674

Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.

G Williams, D Kerle, S Griffin, H Dunlop, S R Bloom.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6239674      PMCID: PMC1443905          DOI: 10.1136/bmj.289.6458.1580

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  3 in total

1.  Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.

Authors:  D Kerle; G Williams; H Ware; S R Bloom
Journal:  Br Med J (Clin Res Ed)       Date:  1984-08-25

2.  Prostatic cancer: treatment with long-acting LHRH analogue.

Authors:  G Williams; J M Allen; J P O'Shea; K Mashiter; A Doble; S R Bloom
Journal:  Br J Urol       Date:  1983-12

3.  Desmopressin response of enuretic children. Effects of age and frequency of enuresis.

Authors:  E M Post; R A Richman; P R Blackett; K P Duncan; K Miller
Journal:  Am J Dis Child       Date:  1983-10
  3 in total
  4 in total

1.  The first clinical use of depot buserelin for advanced prostatic carcinoma.

Authors:  J H Waxman; J Sandow; A Man; M J Barnett; W F Hendry; G M Besser; R T Oliver; P J Magill
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Gonadotrophin hormone releasing analogues open new doors in cancer treatment.

Authors:  J Waxman
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-31

3.  Endocrine treatment of prostatic cancer.

Authors:  G Williams
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

4.  A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer.

Authors:  J Waxman; J Sandow; H Thomas; N James; G Williams
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.